* Lucira Health Inc LHDX.OQ LHDX.O is expected to report
results on August 12.
* The Emeryville, California-based company is expected to report
revenue of $8 million, according to the mean estimate from 3
analysts, based on Refinitiv data.
* Refinitiv's mean analyst estimate for Lucira Health Inc is
for a loss of 32 cents per share.
* The current average analyst rating on the shares is "hold" and
the breakdown of recommendations is 1 "strong buy" or "buy," 1
"hold" and 1 "sell" or "strong sell."
* The mean earnings estimate of analysts had risen by about 2.0%
in the last three months.
* Wall Street's median 12-month price target for Lucira Health
Inc is $8.5, about 2.9% above its last closing price
of $8.25.
* Previous quarterly performance (using preferred earnings
measure in US dollars).
QUARTER STARMINE REFINITIV ACTUAL BEAT, SURPRI
ENDING SMARTESTIM IBES MET, SE %
ATE® ESTIMATE MISSED
Mar. 31 2021 -0.33 -0.33 -0.54 Missed -63.6
This summary was machine generated August 10 at 22:53 GMT. All
figures in US dollars unless otherwise stated